Immune Thrombocytopenic Purpura (ITP) Market Size Was Valued at USD 3,800 Million in 2024, Poised for Significant Growth

The Immune Thrombocytopenic Purpura (ITP) market size across the 7MM was valued at approximately USD 3,800 million in 2024 and is projected to expand at a notable CAGR over the forecast period. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Immune Thrombocytopenia Purpura landscape.

In 2024, the United States captured the largest portion of the total ITP market across the 7MM, accounting for roughly 66% of overall market share. Within the EU4 and the UK, the UK represented the leading ITP market, contributing nearly 30% of the combined regional market share in 2024. Meanwhile, Japan’s ITP market was valued at close to USD 200 million in 2024 and is projected to grow further by 2034.

In 2024, Thrombopoietin Receptor Agonists (TPO-RAs) dominated the ITP market, accounting for the largest share of overall revenue. During the same year, NPLATE/ROMIPLATE emerged as the leading therapy across the 7MM, followed by PROMACTA/REVOLADE. The current ITP treatment landscape includes thrombopoietin receptor agonists such as PROMACTA, NPLATE, and DOPTELET, anti-CD20 monoclonal antibodies like RITUXAN, Syk inhibitors including TAVALISSE/TAVLESSE, neonatal Fc receptor inhibitors such as VYVGART, along with a range of immunomodulatory therapies.

VYVGART, approved in Japan for the treatment of adults with primary ITP, is expected to surpass competing therapies by offering a more durable platelet response while maintaining a favorable and consistent safety profile, as evidenced by results from the pivotal Phase III ADVANCE-IV trial.

The introduction of novel therapeutic classes in ITP such as BTK inhibitors, anti-CD38 antibodies, CXCR5 antagonists, and BAFF/APRIL antagonists demonstrates considerable promise. In 2024, the total number of ITP cases across the 7MM was estimated at approximately 186,000, with projections indicating growth through 2034 over the forecast period. Among these markets, the United States recorded the highest prevalence of ITP compared with the EU4, the UK, and Japan. Within the EU4 and the UK, Germany reported the largest number of ITP cases at around 19,000 in 2024, while Spain had the lowest case count.

DelveInsight’s report  “Immune Thrombocytopenia Purpura Market Insights, Epidemiology, and Market Forecast-2034”, provides a comprehensive analysis of the Immune Thrombocytopenia Purpura landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Immune Thrombocytopenia Purpura market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives. 

To Know in detail about the Immune Thrombocytopenia Purpura market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Immune Thrombocytopenia Purpura Market Forecast

Some of the key facts of the Immune Thrombocytopenia Purpura Market Report:

• ITP is more prevalent in females, with a notably higher prevalence compared to males.
• Patients with ITP are typically diagnosed in adults as compared to children.
• Key Immune Thrombocytopenia Purpura Companies: Rigel Pharmaceuticals, Kissei Pharmaceutical and Grifols, Sobi (Dova Pharmaceuticals) and Asahi Kasei Pharma, Amgen, Argenx, Zenyaku Kogyo and Chugai Pharmaceutical, Novartis, Takeda (Millennium Pharmaceutical), Pfizer, Genosco and Oscotec, Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others
• Key Immune Thrombocytopenia Purpura Therapies: TAVALISSE/TAVLESSE (fostamatinib disodium hexahydrate), DOPTELET (avatrombopag), NPLATE/ROMIPLATE (romiplostim, AMG-531), VYVGART (efgartigimod alfa-fcab, ARGX-113), RITUXAN (rituximab), Ianalumab (VAY736), Mezagitamab (TAK-079), PF-06835375, Cevidoplenib, BT-595 (IgG Next Generation), Efgartigimod (ARGX-113), Rilzabrutinib(PRN-1008), Fostamatinib disodium, PRN1008, LGD-4665, Octagam 10%, Sym001, R788, Eltrombopag, Romiplostim, Hetrombopag Olamine, Rituxan, Cyclophosphamide, Vincristine, Prednisone, Methylprednisolone and IVIG, rituximab [MabThera/Rituxan], PG2, and others
• The Immune Thrombocytopenia Purpura epidemiology based on gender analyzed that the majority of cases of ITP are found in females as compared to the male population.
• The Immune Thrombocytopenia Purpura market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Immune Thrombocytopenia Purpura pipeline products will significantly revolutionize the Immune Thrombocytopenia Purpura market dynamics.

Immune Thrombocytopenia Purpura Overview

Immune Thrombocytopenia Purpura (ITP) is an autoimmune disorder in which the immune system mistakenly attacks and destroys platelets, the blood cells responsible for clotting. This leads to a low platelet count, increasing the risk of bruising, bleeding, and petechiae (small red or purple spots on the skin). ITP can be acute or chronic and may occur in both children and adults, with causes often linked to infections, medications, or other autoimmune conditions.
 
Get a Free sample for the Immune Thrombocytopenia Purpura Market Report:

https://www.delveinsight.com/report-store/immune-thrombocytopenic-purpura-itp-market

Key Trends in Immune Thrombocytopenia Purpura Therapeutics Market:

• Emergence of Novel Targeted Therapies: Development of new agents such as next‑generation thrombopoietin receptor agonists (TPO‑RAs) and biologics is expanding treatment options with improved efficacy and safety profiles.
• Shift Toward Personalized Medicine: Precision treatment strategies based on patient characteristics, disease severity, and response patterns are gaining traction, leading to more tailored care.
• Increased Focus on Long‑Acting Formulations: Extended‑duration therapies and novel delivery systems are improving patient convenience, adherence, and quality of life.
• Growing Awareness and Early Diagnosis: Enhanced education among healthcare providers and patients is driving earlier detection and more appropriate management of ITP.
• Supportive Regulatory Environment: Orphan drug designations and accelerated approval pathways are encouraging innovation and faster market entry of new therapies.

Immune Thrombocytopenia Purpura Epidemiology

The Immune Thrombocytopenia Purpura epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Immune Thrombocytopenia Purpura Epidemiology Segmentation:

The Immune Thrombocytopenia Purpura market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of ITP
• Age-specific Diagnosed Prevalent Cases of ITP
• Gender-specific Diagnosed Prevalent Cases of ITP

Download the report to understand which factors are driving Immune Thrombocytopenia Purpura epidemiology trends @ Immune Thrombocytopenia Purpura Epidemiology Forecast

Recent Development In The Immune Thrombocytopenia Purpura Treatment Landscape:

• In July 2025, Sobi announced that the US Food and Drug Administration (FDA) has approved DOPTELET (avatrombopag) for the treatment of thrombocytopenia in pediatric patients aged one year and older with persistent or chronic ITP who have had an insufficient response to prior therapy.
• In June 2025, Novartis presented an oral abstract (Abstract #S312) of Phase II results from the VAYHIT3 study, evaluating Ianalumab in patients with primary ITP previously treated with at least two lines of therapy.
• In April 2025, as per the news released in April 2025, Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines including ITP. Further, the target action date for the FDA regulatory decision for ITP, is August 29, 2025 for which the drug was granted fast track designation earlier in November 2020.

Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Immune Thrombocytopenia Purpura market or expected to get launched during the study period. The analysis covers Immune Thrombocytopenia Purpura market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Immune Thrombocytopenia Purpura Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Immune Thrombocytopenia Purpura Therapies and Key Companies

• TAVALISSE/TAVLESSE (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals, Kissei Pharmaceutical and Grifols
• DOPTELET (avatrombopag): Sobi (Dova Pharmaceuticals) and Asahi Kasei Pharma
• NPLATE/ROMIPLATE (romiplostim, AMG-531): Amgen
• VYVGART (efgartigimod alfa-fcab, ARGX-113): Argenx
• RITUXAN (rituximab): Zenyaku Kogyo and Chugai Pharmaceutical
• Ianalumab (VAY736): Novartis
• Mezagitamab (TAK-079): Takeda (Millennium Pharmaceutical)
• PF-06835375: Pfizer
• Cevidoplenib: Genosco and Oscotec
• BT-595 (IgG Next Generation): Biotest
• Efgartigimod (ARGX-113): Argenx
• Rilzabrutinib(PRN-1008): Sanofi/ Principia Biopharma
• Fostamatinib disodium: Rigel Pharmaceuticals
• PRN1008: Principia Biopharma
• LGD-4665: GlaxoSmithKline
• Octagam 10%: Octapharma
• Sym001: Symphogen A/S
• R788: Kissei Pharma
• BMS-986004: BMS-986004
• Eltrombopag: GlaxoSmithKline
• Romiplostim: Amgen
• Hetrombopag Olamine: Jiangsu HengRui Medicine
• Rituxan, Cyclophosphamide, Vincristine, Prednisone: Genentech, Inc.
• Methylprednisolone and IVIG: Bayer
• rituximab [MabThera/Rituxan]: Hoffmann-La Roche
• PG2: PhytoHealth Corporation

Discover more about therapies set to grab major Immune Thrombocytopenia Purpura market share @ Immune Thrombocytopenia Purpura Treatment Market

Immune Thrombocytopenia Purpura Market Drivers

• Rising Prevalence of ITP: Increasing cases of autoimmune disorders and platelet-related conditions are driving market demand.
• Advancements in Therapeutics: Development of novel treatments, including thrombopoietin receptor agonists and biologics, is expanding therapy options.
• Growing Awareness and Early Diagnosis: Enhanced physician and patient awareness enables timely diagnosis and treatment initiation.
• Supportive R&D and Funding: Increased investment in ITP research and clinical trials fosters innovation and market growth.
• Favorable Regulatory Environment: Orphan drug incentives and expedited approvals encourage development of new therapies.

Immune Thrombocytopenia Purpura Market Barriers

• High Treatment Costs: Expensive therapies and long-term management limit patient access, particularly in developing regions.
• Side Effects and Safety Concerns: Adverse reactions associated with current treatments can reduce patient compliance.
• Limited Curative Options: Most available therapies manage symptoms rather than providing a definitive cure.
• Market Fragmentation: Variations in healthcare infrastructure and treatment adoption across regions restrict uniform growth.
• Complex Disease Management: Chronic and recurrent nature of ITP requires ongoing monitoring and individualized treatment, complicating care delivery.

Scope of the Immune Thrombocytopenia Purpura Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Immune Thrombocytopenia Purpura Companies: Rigel Pharmaceuticals, Kissei Pharmaceutical and Grifols, Sobi (Dova Pharmaceuticals) and Asahi Kasei Pharma, Amgen, Argenx, Zenyaku Kogyo and Chugai Pharmaceutical, Novartis, Takeda (Millennium Pharmaceutical), Pfizer, Genosco and Oscotec, Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others
• Key Immune Thrombocytopenia Purpura Therapies: TAVALISSE/TAVLESSE (fostamatinib disodium hexahydrate), DOPTELET (avatrombopag), NPLATE/ROMIPLATE (romiplostim, AMG-531), VYVGART (efgartigimod alfa-fcab, ARGX-113), RITUXAN (rituximab), Ianalumab (VAY736), Mezagitamab (TAK-079), PF-06835375, Cevidoplenib, BT-595 (IgG Next Generation), Efgartigimod (ARGX-113), Rilzabrutinib(PRN-1008), Fostamatinib disodium, PRN1008, LGD-4665, Octagam 10%, Sym001, R788, Eltrombopag, Romiplostim, Hetrombopag Olamine, Rituxan, Cyclophosphamide, Vincristine, Prednisone, Methylprednisolone and IVIG, rituximab [MabThera/Rituxan], PG2, and others
• Immune Thrombocytopenia Purpura Therapeutic Assessment: Immune Thrombocytopenia Purpura current marketed and Immune Thrombocytopenia Purpura emerging therapies
• Immune Thrombocytopenia Purpura Market Dynamics: Immune Thrombocytopenia Purpura market drivers and Immune Thrombocytopenia Purpura market barriers
• Immune Thrombocytopenia Purpura Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Immune Thrombocytopenia Purpura Unmet Needs, KOL’s views, Analyst’s views, Immune Thrombocytopenia Purpura Market Access and Reimbursement 

To know more about Immune Thrombocytopenia Purpura companies working in the treatment market, visit @ Immune Thrombocytopenia Purpura Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.